Industry
Biotechnology
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Avi Kapoor
August 14, 2024 | 12:35 pm
Portfolio Pulse from Benzinga Insights
August 13, 2024 | 5:35 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 6:06 am
Portfolio Pulse from Avi Kapoor
July 30, 2024 | 2:13 pm
Portfolio Pulse from Benzinga Newsdesk
July 22, 2024 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 11:01 am
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 4:02 pm
Portfolio Pulse from Vandana Singh
June 27, 2024 | 1:49 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 1:45 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 10:24 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.